Free tool
FAERS Monitor: Vyndaqel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211996 or its brand name (Vyndaqel, Tafamidis Meglumine). Reports on generic versions are filed under their own applications.
Reports
4,834
Serious
4,224
87% of reports
Hospitalization
1,470
Death reported
1,920
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death1,404
- cardiac failure537
- off label use417
- dyspnoea240
- cardiac failure chronic194
- product use in unapproved indication190
- atrial fibrillation182
- fatigue174
- condition aggravated159
- disease progression146
- asthenia135
- fall134
- dizziness129
- diarrhoea104
- weight decreased101
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 22 |
| 2016 | 10 |
| 2017 | 10 |
| 2018 | 30 |
| 2019 | 637 |
| 2020 | 833 |
| 2021 | 583 |
| 2022 | 750 |
| 2023 | 429 |
| 2024 | 478 |
| 2025 | 663 |
| 2026 | 378 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,325 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cardiac failure chronicSignal | 194 | 207.5 | 180.1 | 37,858 |
| cardiac failureSignal | 537 | 29.3 | 27.0 | 14,605 |
| atrial fibrillationSignal | 182 | 8.1 | 7.1 | 1,137 |
| deathSignal | 1,404 | 7.1 | 6.8 | 7,655 |
| disease progressionSignal | 146 | 5.4 | 4.6 | 518 |
| product use in unapproved indicationSignal | 190 | 3.3 | 2.9 | 312 |
| condition aggravatedSignal | 159 | 2.3 | 2.0 | 114 |
| off label useSignal | 417 | 2.1 | 1.9 | 240 |
| dyspnoea | 240 | 1.8 | 1.6 | 95 |
| fall | 134 | 1.8 | 1.5 | 43 |
| weight decreased | 101 | 1.6 | 1.3 | 21 |
| asthenia | 135 | 1.6 | 1.3 | 27 |
| dizziness | 129 | 1.1 | 0.9 | 2 |
| fatigue | 174 | 1.0 | 0.8 | 0 |
| diarrhoea | 104 | 0.7 | 0.6 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.